Izindaba

I-NEW DelHI, Juni 22 (Xinhua) - Umkhiqizi wokugoma waseNdiya i-Bharat Biotech's Covaxin ukhombise ukusebenza ngempumelelo okungamaphesenti angama-77.8 ezivivinyweni zesigaba sesi-III, kubike abezindaba abaningi basekhaya ngoLwesibili.

"I-Bharat Biotech's Covaxin isebenza ngamaphesenti angama-77.8 ekuvikeleni i-COVID-19, ngokusho kwedatha evela ezivivinyweni zesigaba III ezenziwa kubahlanganyeli abangama-25,800 kulo lonke elaseNdiya," kusho umbiko.

Izinga lokusebenza liphume ngoLwesibili ngemuva kokuthi ikomiti lochwepheshe be-Drugs Controller of India (DCGI) (SEC) lihlangane ladingida imiphumela.

Inkampani eyenza imithi ithumele idatha yocwaningo lwesigaba sesi-III yomuthi wokugoma ku-DCGI ngempelasonto.

Imibiko ithe inkampani kulindeleke ukuthi ibambe umhlangano "owethulwe ngaphambili" neziphathimandla zeWorld Health Organisation ngoLwesithathu, ukudingida izinkombandlela zokulethwa kokugcina kwemininingwane nemibhalo edingekayo.

I-India yaqala ukugomela abantu abaningi nge-COVID-19 ngoJan. 16 ngokunikeza imigomo emibili eyenziwe e-India, okuyi-Covishield ne-Covaxin.

I-Serum Institute of India (SII) yenza i-AstraZeneca-Oxford University's Covishield, kuyilapho i-Bharat Biotech ibambisene noMkhandlu WaseNdiya Wocwaningo Lwezokwelapha (ICMR) ekukhiqizeni i-Covaxin.

Umuthi wokugomela iSputnik V owenziwe eRussia nawo wenziwa kuleli.Enditem